Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

NCT03386721 ·Status: TERMINATED ·Phase: PHASE2

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

NCT03111901 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors

NCT07001592 ·Status: RECRUITING ·Phase: PHASE1

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

NCT01583686 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

NCT03991130 ·Status: TERMINATED ·Phase: PHASE2

A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors

NCT02350673 ·Status: COMPLETED ·Phase: PHASE1

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

CART-meso in Mesothelin Expressing Cancers

NCT02159716 ·Status: COMPLETED ·Phase: PHASE1

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety of Intranodal ECI-006 in Melanoma Patients

NCT03394937 ·Status: TERMINATED ·Phase: PHASE1

Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

NCT01593670 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

NCT02580747 ·Status: UNKNOWN ·Phase: PHASE1

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

NCT00704938 ·Status: TERMINATED ·Phase: PHASE2

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

NCT01876212 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

NCT00031564 ·Status: COMPLETED ·Phase: PHASE2

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

NCT03325101 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

NCT03970382 ·Status: SUSPENDED ·Phase: PHASE1

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00091338 ·Status: COMPLETED ·Phase: PHASE1

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

NCT01218867 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

NCT06318871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

Modified Vaccine for High Risk or Low Residual Melanoma Patients

NCT01898039 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

NCT01632332 ·Status: COMPLETED ·Phase: PHASE1

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

NCT00003002 ·Status: COMPLETED ·Phase: PHASE1

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

NCT06239220 ·Status: RECRUITING ·Phase: PHASE2